UNSPSC 51151514: Pyridostigmine

This classification denotes an acetylcholinesterase inhibitor with the molecular formula C9H13N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19QM69HH21, chemically known as pyridinium, 3-hydroxy-1-methyl-, dimethylcarbamate (ester) but generally known as pyridostigmine, which bears US NIH Compound Identifier 4991. European Medicines Agency schedules Pyridostigmine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15059MIG.

UNSPSC 51151514 Pyridostigmine is a Commodity code that does not show relevant recent state and local procurement activity. The code's two recent opportunities—Seminole County's procurement of naloxone and drug deactivation systems (IFB60459723LAS) and Texas HHS Commission's Request for Information on direct-to-manufacturer prescription programs (RFI HHS0017013)—both address pharmaceutical products and pharmacy benefit management but neither explicitly solicits pyridostigmine or cholinesterase inhibitors for which the code is named. The Seminole County bid targets naloxone, an opioid antagonist used for overdose reversal, while the Texas RFI explores broader pharmacy supply-chain restructuring outside traditional pharmacy benefit manager arrangements. Neither opportunity provides a concrete framing of state and local demand for pyridostigmine specifically.

The mismatch between the code's scope and actual recent state and local solicitations suggests that pyridostigmine procurement either occurs under different codes, flows through state pharmacy benefit plans or group purchasing organizations without discrete competitive solicitations, or remains inactive at the state and local level during this period. Practitioners evaluating this code should verify whether relevant opportunities are tagged differently or obtain directly from state pharmacy procurement offices—particularly state Medicaid programs and corrections departments, which typically stock the drug for neuromuscular conditions and myasthenia gravis management—rather than rely on recent public solicitation activity to gauge current demand.